Form 4: Eledon Pharmaceuticals President Receives Stock Grant
Insider Transaction (Form 4)
Steven Perrin, President and a Director of Eledon Pharmaceuticals, Inc., reported multiple transactions in common stock on July 31, 2026.
Summary
- Grant/award: acquired 152,353 Common Stock on July 31, 2026; holds 153,353 after (Direct).
- Tax/exercise-price withholding: disposed of 72,138 Common Stock at $3.38 ($243,826) on July 31, 2026; holds 81,215 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Steven Perrin — Director, Officer (President)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Grant/award | Common Stock | 152,353 | — | — | 153,353 |
| 2026-07-31 | Tax/exercise-price withholding | Common Stock | 72,138 | $3 | $243.8K | 81,215 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Grant/award (152,353 shares) |
| 2026-07-31 | Tax/exercise-price withholding (72,138 shares) |
Keywords
insider transaction, Form 4, ELDN, Eledon Pharmaceuticals, Inc., neutral, Steven Perrin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.